# TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

> **NCT05496569** · PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 26 (actual)

## Conditions studied

- Dedifferentiated Liposarcoma

## Interventions

- **DRUG:** TQB3616 capsule
- **DRUG:** TQB3616 placebo

## Key facts

- **NCT ID:** NCT05496569
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-08
- **Primary completion:** 2024-06-15
- **Final completion:** 2025-09-28
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496569, "TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05496569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*